BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Osborne V, Davies M, Layton D, Shakir SAW. Utilisation and Safety of Deferasirox: Results from an Observational Cohort Study in England. Drug Saf 2018;41:267-75. [PMID: 29019038 DOI: 10.1007/s40264-017-0606-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Goetz V, Yang DD, Lacaille F, Pelosi M, Angoulvant F, Brassier A, Arnoux J, Schiff M, Heilbronner C, Salvador E, Debray D, Oualha M, Renolleau S, Girard M, de Lonlay P. What are the clues for an inherited metabolic disorder in Reye syndrome? A single Centre study of 58 children. Molecular Genetics and Metabolism 2022. [DOI: 10.1016/j.ymgme.2022.02.001] [Reference Citation Analysis]
2 Grech L, Sultana J, Borg K, Borg J. Drug safety in thalassemia: lessons from the present and directions for the future. Expert Opin Drug Saf 2021;20:937-47. [PMID: 33877003 DOI: 10.1080/14740338.2021.1919081] [Reference Citation Analysis]
3 Zengin Ersoy G, Ayçiçek A, Odaman Al I, Bayram C, Arslantaş E, Özdemir GN, Uysalol EP, Şalcıoğlu Z, Akıcı F, Aydoğan G. Safety and efficacy of deferasirox in patients with transfusion-dependent thalassemia: A 4-year single-center experience. Pediatr Hematol Oncol 2021;38:555-63. [PMID: 33749500 DOI: 10.1080/08880018.2021.1901809] [Reference Citation Analysis]
4 Babu T, Panachiyil GM, Sebastian J, Ravi MD. Effectiveness and tolerability of twice daily dosing of deferasirox in unresponsive and intolerant transfusion-dependent beta-thalassemia patients: A narrative review. Indian J Pharmacol 2020;52:514-9. [PMID: 33666193 DOI: 10.4103/ijp.IJP_333_19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Cao K, Ren G, Lu C, Wang Y, Tan Y, Zhou J, Zhang Y, Lu Y, Li N, Chen X, Zhao D. ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects. Eur J Clin Pharmacol 2020;76:51-9. [DOI: 10.1007/s00228-019-02775-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Tataranni T, Mazzoccoli C, Agriesti F, De Luca L, Laurenzana I, Simeon V, Ruggieri V, Pacelli C, Della Sala G, Musto P, Capitanio N, Piccoli C. Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells. Stem Cell Res Ther 2019;10:171. [PMID: 31196186 DOI: 10.1186/s13287-019-1293-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
7 Moukalled NM, Bou-Fakhredin R, Taher AT. Deferasirox: Over a Decade of Experience in Thalassemia. Mediterr J Hematol Infect Dis 2018;10:e2018066. [PMID: 30416698 DOI: 10.4084/MJHID.2018.066] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]